{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T02:07:17Z","timestamp":1779502037309,"version":"3.53.1"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12012-026-10107-w","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:12:16Z","timestamp":1776409936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the Apelin\u2013APJ Axis: A Promising Strategy to Mitigate Anthracycline-Induced Cardiotoxicity"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-3801","authenticated-orcid":false,"given":"Varsha G.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"10107_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. The New England Journal of Medicine, 339, 900\u2013905.","journal-title":"The New England Journal of Medicine"},{"key":"10107_CR2","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho, C., Santos, R. X., Cardoso, S., Correia, S., Oliveira, P. J., Santos, M. S., & Moreira, P. I. (2009). Doxorubicin: The good, the bad and the ugly effect. Current Medicinal Chemistry, 16, 3267\u20133285.","journal-title":"Current Medicinal Chemistry"},{"key":"10107_CR3","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., Fiorentini, C., & Cipolla, C. M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131, 1981\u20131988.","journal-title":"Circulation"},{"key":"10107_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/hrt.2007.136093","volume":"94","author":"SE Lipshultz","year":"2008","unstructured":"Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008). Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart, 94, 525\u2013533.","journal-title":"Heart"},{"key":"10107_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M., & Muggia, F. M. (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710\u2013717.","journal-title":"Annals of Internal Medicine"},{"key":"10107_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., & Leisenring, W. M. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ (Clinical research ed.), 339, Article b4606.","journal-title":"BMJ (Clinical research ed.)"},{"key":"10107_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","volume":"125","author":"K Shan","year":"1996","unstructured":"Shan, K., Lincoff, A. M., & Young, J. B. (1996). Anthracycline-induced cardiotoxicity. Annals of Internal Medicine, 125, 47\u201358.","journal-title":"Annals of Internal Medicine"},{"key":"10107_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00246-010-9878-3","volume":"32","author":"BH Trachtenberg","year":"2011","unstructured":"Trachtenberg, B. H., Landy, D. C., Franco, V. I., Henkel, J. M., Pearson, E. J., Miller, T. L., & Lipshultz, S. E. (2011). Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology, 32, 342\u2013353.","journal-title":"Pediatric Cardiology"},{"key":"10107_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/jcdd12060207","volume":"12","author":"V Bhutani","year":"2025","unstructured":"Bhutani, V., Varzideh, F., Wilson, S., Kansakar, U., Jankauskas, S. S., & Santulli, G. (2025). Doxorubicin-induced cardiotoxicity: A comprehensive update. Journal of Cardiovascular Development and Disease, 12, 207.","journal-title":"Journal of Cardiovascular Development and Disease"},{"key":"10107_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/med.21280","volume":"34","author":"FS Carvalho","year":"2014","unstructured":"Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014). Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Medical Research Reviews, 34, 106\u2013135.","journal-title":"Medical Research Reviews"},{"key":"10107_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117312","volume":"179","author":"H Li","year":"2024","unstructured":"Li, H., Wang, M., & Huang, Y. (2024). Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective. Biomedicine & Pharmacotherapy, 179, Article 117312.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10107_CR12","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5624","author":"G Qing","year":"2025","unstructured":"Qing, G., Huang, C., Pei, J., & Peng, B. (2025). Alteration of cardiac energetics and mitochondrial function in doxorubicin\u2011induced cardiotoxicity: Molecular mechanism and prospective implications (Review). International Journal of Molecular Medicine. https:\/\/doi.org\/10.3892\/ijmm.2025.5624","journal-title":"International Journal of Molecular Medicine"},{"key":"10107_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy, 139, Article 111708.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10107_CR14","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00018-020-03729-y","volume":"78","author":"AJ Wang","year":"2021","unstructured":"Wang, A. J., Zhang, J., Xiao, M., Wang, S., Wang, B. J., Guo, Y., Tang, Y., & Gu, J. (2021). Molecular mechanisms of doxorubicin-induced cardiotoxicity: Novel roles of sirtuin 1-mediated signaling pathways. Cellular and Molecular Life Sciences, 78, 3105\u20133125.","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10107_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","volume":"126","author":"KB Wallace","year":"2020","unstructured":"Wallace, K. B., Sardao, V. A., & Oliveira, P. J. (2020). Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy. Circulation Research, 126, 926\u2013941.","journal-title":"Circulation Research"},{"key":"10107_CR16","first-page":"10","volume":"25","author":"C Myers","year":"1998","unstructured":"Myers, C. (1998). The role of iron in doxorubicin-induced cardiomyopathy. Seminars in Oncology, 25, 10\u201314.","journal-title":"Seminars in Oncology"},{"key":"10107_CR17","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.7150\/ijbs.97263","volume":"20","author":"X Wen","year":"2024","unstructured":"Wen, X., Tang, S., Wan, F., Zhong, R., Chen, L., & Zhang, H. (2024). The PI3K\/Akt-Nrf2 signaling pathway and mitophagy synergistically mediate hydroxytyrosol to alleviate intestinal oxidative damage. International Journal of Biological Sciences, 20, 4258\u20134276.","journal-title":"International Journal of Biological Sciences"},{"key":"10107_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01565-0","volume":"9","author":"X Zhao","year":"2023","unstructured":"Zhao, X., Tian, Z., Sun, M., & Dong, D. (2023). Nrf2: A dark horse in doxorubicin-induced cardiotoxicity. Cell Death Discovery, 9, Article 261.","journal-title":"Cell Death Discovery"},{"key":"10107_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7582730","volume":"2018","author":"S Gorini","year":"2018","unstructured":"Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018). Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. Oxidative Medicine and Cellular Longevity, 2018, Article 7582730.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10107_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","volume":"200","author":"PJ Oliveira","year":"2004","unstructured":"Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004). Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicology and Applied Pharmacology, 200, 159\u2013168.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10107_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12012-024-09941-7","volume":"25","author":"C Pal","year":"2025","unstructured":"Pal, C. (2025). Small molecules targeting mitochondria: A mechanistic approach to combating doxorubicin-induced cardiotoxicity. Cardiovascular Toxicology, 25, 216\u2013247.","journal-title":"Cardiovascular Toxicology"},{"key":"10107_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","volume":"30","author":"GC Pereira","year":"2016","unstructured":"Pereira, G. C., Pereira, S. P., Tavares, L. C., Carvalho, F. S., Magalh\u00e3es-Novais, S., Barbosa, I. A., Santos, M. S., Bjork, J., Moreno, A. J., Wallace, K. B., & Oliveira, P. J. (2016). Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function. Mitochondrion, 30, 95\u2013104.","journal-title":"Mitochondrion"},{"key":"10107_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116881","volume":"236","author":"A Sripusanapan","year":"2025","unstructured":"Sripusanapan, A., Piriyakulthorn, C., Apaijai, N., Chattipakorn, S. C., & Chattipakorn, N. (2025). Ivabradine ameliorates doxorubicin-induced cardiotoxicity through improving mitochondrial function and cardiac calcium homeostasis. Biochemical Pharmacology, 236, Article 116881.","journal-title":"Biochemical Pharmacology"},{"key":"10107_CR24","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"ZV Varga","year":"2015","unstructured":"Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015). Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 309, H1453-1467.","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10107_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.taap.2016.02.003","volume":"295","author":"V Vijay","year":"2016","unstructured":"Vijay, V., Moland, C. L., Han, T., Fuscoe, J. C., Lee, T., Herman, E. H., Jenkins, G. R., Lewis, S. M., Cummings, C. A., Gao, Y., Cao, Z., Yu, L. R., & Desai, V. G. (2016). Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice. Toxicology and Applied Pharmacology, 295, 68\u201384.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10107_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062434","author":"H Zhang","year":"2025","unstructured":"Zhang, H., Wang, Y., Wang, R., Yi, Q., Xu, H., Tan, B., & Zhu, J. (2025). Kartogenin improves doxorubicin-induced cardiotoxicity by alleviating oxidative stress and protecting mitochondria. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms26062434","journal-title":"International Journal of Molecular Sciences"},{"key":"10107_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm, K. N., & Tyler, D. J. (2020). The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovascular Drugs and Therapy, 34, 255\u2013269.","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10107_CR28","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1111\/jcmm.15305","volume":"24","author":"N Osataphan","year":"2020","unstructured":"Osataphan, N., Phrommintikul, A., Chattipakorn, S. C., & Chattipakorn, N. (2020). Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. Journal of Cellular and Molecular Medicine, 24, 6534\u20136557.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10107_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2014.05.017","volume":"737","author":"J Guo","year":"2014","unstructured":"Guo, J., Guo, Q., Fang, H., Lei, L., Zhang, T., Zhao, J., & Peng, S. (2014). Cardioprotection against doxorubicin by metallothionein is associated with preservation of mitochondrial biogenesis involving PGC-1\u03b1 pathway. European Journal of Pharmacology, 737, 117\u2013124.","journal-title":"European Journal of Pharmacology"},{"key":"10107_CR30","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1007\/s00204-025-04006-2","volume":"99","author":"SR Brand\u00e3o","year":"2025","unstructured":"Brand\u00e3o, S. R., Lazzari, E., Vitorino, R., Meroni, G., Reis-Mendes, A., Neuparth, M. J., Amado, F., Carvalho, F., Ferreira, R., & Costa, V. M. (2025). Comprehensive ubiquitome analysis reveals persistent mitochondrial remodeling disruptions from doxorubicin-induced cardiotoxicity in aged CD-1 male mice. Archives of Toxicology, 99, 2447\u20132462.","journal-title":"Archives of Toxicology"},{"key":"10107_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35, 495\u2013516.","journal-title":"Toxicologic Pathology"},{"key":"10107_CR32","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1006\/jmcc.2002.2110","volume":"34","author":"S Wu","year":"2002","unstructured":"Wu, S., Ko, Y. S., Teng, M. S., Ko, Y. L., Hsu, L. A., Hsueh, C., Chou, Y. Y., Liew, C. C., & Lee, Y. S. (2002). Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: In vitro and in vivo studies. Journal of Molecular and Cellular Cardiology, 34, 1595\u20131607.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10107_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1254\/jphs.FP0050980","volume":"101","author":"M Ueno","year":"2006","unstructured":"Ueno, M., Kakinuma, Y., Yuhki, K., Murakoshi, N., Iemitsu, M., Miyauchi, T., & Yamaguchi, I. (2006). Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. Journal of Pharmacological Sciences, 101, 151\u2013158.","journal-title":"Journal of Pharmacological Sciences"},{"key":"10107_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejheart.2007.11.002","volume":"10","author":"A de d'Anglemont Tassigny","year":"2008","unstructured":"de d\u2019Anglemont Tassigny, A., Berdeaux, A., Souktani, R., Henry, P., & Ghaleh, B. (2008). The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1\/2. European Journal of Heart Failure, 10, 39\u201346.","journal-title":"European Journal of Heart Failure"},{"key":"10107_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010961","volume":"8","author":"BA McLean","year":"2019","unstructured":"McLean, B. A., Patel, V. B., Zhabyeyev, P., Chen, X., Basu, R., Wang, F., Shah, S., Vanhaesebroeck, B., & Oudit, G. Y. (2019). PI3K\u03b1 pathway inhibition with doxorubicin treatment results in distinct biventricular atrophy and remodeling with right ventricular dysfunction. Journal of the American Heart Association, 8, Article e010961.","journal-title":"Journal of the American Heart Association"},{"key":"10107_CR36","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1006\/jmcc.2002.2068","volume":"34","author":"Y Taniyama","year":"2002","unstructured":"Taniyama, Y., & Walsh, K. (2002). Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. Journal of Molecular and Cellular Cardiology, 34, 1241\u20131247.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10107_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2025.119960","volume":"1872","author":"G Xiang","year":"2025","unstructured":"Xiang, G., Shi, T., Nwaele, C. O., Xiao, H., Liu, Y., Wang, Q., Zhang, J., & Zheng, Y. (2025). Inhibition of the Sp1\/PI3K\/AKT signaling pathway exacerbates doxorubicin-induced cardiomyopathy. Biochimica et Biophysica Acta, 1872, Article 119960.","journal-title":"Biochimica et Biophysica Acta"},{"key":"10107_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1385\/CT:5:3:269","volume":"5","author":"RD Olson","year":"2005","unstructured":"Olson, R. D., Gambliel, H. A., Vestal, R. E., Shadle, S. E., Charlier, H. A., Jr., & Cusack, B. J. (2005). Doxorubicin cardiac dysfunction: Effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovascular Toxicology, 5, 269\u2013283.","journal-title":"Cardiovascular Toxicology"},{"key":"10107_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/jat.4405","volume":"43","author":"VG Desai","year":"2023","unstructured":"Desai, V. G., Azevedo-Pouly, A., Vijay, V., Phanavanh, B., Moland, C. L., Han, T., Revollo, J., Aryal, B., Rao, V. A., & Fuscoe, J. C. (2023). Potential role of the apelin-APJ pathway in sex-related differential cardiotoxicity induced by doxorubicin in mice. Journal of Applied Toxicology, 43, 557\u2013576.","journal-title":"Journal of Applied Toxicology"},{"key":"10107_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074675","volume":"8","author":"A Gupta","year":"2013","unstructured":"Gupta, A., Rohlfsen, C., Leppo, M. K., Chacko, V. P., Wang, Y., Steenbergen, C., & Weiss, R. G. (2013). Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. PLoS One, 8, Article e74675.","journal-title":"PLoS One"},{"key":"10107_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/toxsci\/kfz026","volume":"169","author":"GC Pereira","year":"2019","unstructured":"Pereira, G. C., Pereira, S. P., Pereira, F. B., Louren\u00e7o, N., Lumini, J. A., Pereira, C. V., Bjork, J. A., Magalh\u00e3es, J., Ascens\u00e3o, A., Wieckowski, M. R., Moreno, A. J., Wallace, K. B., & Oliveira, P. J. (2019). Early Cardiac Mitochondrial Molecular and Functional Responses to Acute Anthracycline Treatment in Wistar Rats. Toxicological Sciences, 169, 137\u2013150.","journal-title":"Toxicological Sciences"},{"key":"10107_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.mito.2010.06.001","volume":"11","author":"D Montaigne","year":"2011","unstructured":"Montaigne, D., Marechal, X., Preau, S., Baccouch, R., Modine, T., Fayad, G., Lancel, S., & Neviere, R. (2011). Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion, 11, 22\u201326.","journal-title":"Mitochondrion"},{"key":"10107_CR43","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.pharmtox.45.120403.095802","volume":"45","author":"RD Brown","year":"2005","unstructured":"Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005). The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annual Review of Pharmacology and Toxicology, 45, 657\u2013687.","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10107_CR44","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1006\/jmcc.2002.2090","volume":"34","author":"CS Long","year":"2002","unstructured":"Long, C. S., & Brown, R. D. (2002). The cardiac fibroblast, another therapeutic target for mending the broken heart? Journal of Molecular and Cellular Cardiology, 34, 1273\u20131278.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10107_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pharmthera.2009.05.002","volume":"123","author":"KE Porter","year":"2009","unstructured":"Porter, K. E., & Turner, N. A. (2009). Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacology & Therapeutics, 123, 255\u2013278.","journal-title":"Pharmacology & Therapeutics"},{"key":"10107_CR46","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., & Blaxall, B. C. (2016). Cardiac fibrosis: The fibroblast awakens. Circulation Research, 118, 1021\u20131040.","journal-title":"Circulation Research"},{"key":"10107_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010053","author":"M Telesca","year":"2023","unstructured":"Telesca, M., Donniacuo, M., Bellocchio, G., Riemma, M. A., Mele, E., Dell\u2019Aversana, C., Sgueglia, G., Cianflone, E., Cappetta, D., Torella, D., Altucci, L., Castaldo, G., Rossi, F., Berrino, L., Urbanek, K., & De Angelis, A. (2023). Initial phase of anthracycline cardiotoxicity involves cardiac fibroblasts activation and metabolic switch. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16010053","journal-title":"Cancers (Basel)"},{"key":"10107_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123609","volume":"371","author":"X Cao","year":"2025","unstructured":"Cao, X., Zhao, L., Zhou, J., Ding, S., Sun, Y., Ma, Y., Ma, Z., Liu, H., Dong, T., Luo, A., Li, Y., & Fang, B. (2025). Dexmedetomidine inhibits ferroptosis through the Akt\/GSK3\u03b2\/Nrf2 axis and alleviates adriamycin-induced cardiotoxicity. Life Sciences, 371, Article 123609.","journal-title":"Life Sciences"},{"key":"10107_CR49","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/bph.17423","volume":"182","author":"L Hong","year":"2025","unstructured":"Hong, L., Cai, X., Zhan, Y., Liu, S., Zou, P., Chen, Y., & Shao, L. (2025). TLR2 activates AP-1 to facilitate CTGF transcription and stimulate doxorubicin-induced myocardial injury. British Journal of Pharmacology, 182, 2897\u20132913.","journal-title":"British Journal of Pharmacology"},{"key":"10107_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131386","volume":"393","author":"IM Seropian","year":"2023","unstructured":"Seropian, I. M., Fontana Estevez, F. S., Villaverde, A., Cacciagi\u00fa, L., Bustos, R., Touceda, V., Penas, F., Selser, C., Morales, C., Miksztowicz, V., & Gonz\u00e1lez, G. E. (2023). Galectin-3 contributes to acute cardiac dysfunction and toxicity by increasing oxidative stress and fibrosis in doxorubicin-treated mice. International Journal of Cardiology, 393, Article 131386.","journal-title":"International Journal of Cardiology"},{"key":"10107_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/crp\/2729462","volume":"2025","author":"L Zhang","year":"2025","unstructured":"Zhang, L., & Liu, Y. (2025). MO oxygen therapy prevents doxorubicin-induced cardiotoxicity. Cardiology Research and Practice, 2025, Article 2729462.","journal-title":"Cardiology Research and Practice"},{"key":"10107_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0054-5","volume":"5","author":"N Bansal","year":"2019","unstructured":"Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology, 5, Article 18.","journal-title":"Cardio-Oncology"},{"key":"10107_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","volume":"8","author":"A Ancion","year":"2019","unstructured":"Ancion, A., Tridetti, J., Nguyen Trung, M. L., Oury, C., & Lancellotti, P. (2019). A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: Focus on perindopril. Cardiology and Therapy, 8, 179\u2013191.","journal-title":"Cardiology and Therapy"},{"key":"10107_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/CRD.0000000000000252","volume":"27","author":"JB Blanter","year":"2019","unstructured":"Blanter, J. B., & Frishman, W. H. (2019). The preventive role of angiotensin converting enzyme inhibitors\/angiotensin-II receptor blockers and \u03b2-adrenergic blockers in anthracycline- and trastuzumab-induced cardiotoxicity. Cardiology Review, 27, 256\u2013259.","journal-title":"Cardiology Review"},{"key":"10107_CR55","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/ehf2.15095","volume":"12","author":"G Colombo","year":"2025","unstructured":"Colombo, G., Biering-Sorensen, T., Ferreira, J. P., Lombardi, C. M., Bonelli, A., Garascia, A., Metra, M., & Inciardi, R. M. (2025). Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy. ESC Heart Fail, 12, 1029\u20131044.","journal-title":"ESC Heart Fail"},{"key":"10107_CR56","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin, M., Krischer, J., Tamura, R., Fink, A., Bello-Matricaria, L., McCaskill-Stevens, W., & Munster, P. N. (2019). Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. Journal of the American College of Cardiology, 73, 2859\u20132868.","journal-title":"Journal of the American College of Cardiology"},{"key":"10107_CR57","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter, C., Nielsen, T. H., Edfors, L. R., Linde, C., Bland, J. M., LeWinter, M., Cleland, J. G. F., K\u00f8ber, L., Braunschweig, F., & Mansson-Broberg, A. (2022). A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. European Heart Journal, 43, 2562\u20132569.","journal-title":"European Heart Journal"},{"key":"10107_CR58","volume":"9","author":"EC de Baat","year":"2022","unstructured":"de Baat, E. C., Mulder, R. L., Armenian, S., Feijen, E. A., Grotenhuis, H., Hudson, M. M., Mavinkurve-Groothuis, A. M., Kremer, L. C., & van Dalen, E. C. (2022). Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database of Systematic Reviews, 9, Article Cd014638.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10107_CR59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/CAD.0000000000000514","volume":"28","author":"E Tahover","year":"2017","unstructured":"Tahover, E., Segal, A., Isacson, R., Rosengarten, O., Grenader, T., Gips, M., Cherny, N., Heching, N. I., Mesika, L., Catane, R., & Gabizon, A. (2017). Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: A retrospective cohort study with a comparative analysis of toxicity and survival. Anti-Cancer Drugs, 28, 787\u2013794.","journal-title":"Anti-Cancer Drugs"},{"key":"10107_CR60","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10552-021-01487-1","volume":"32","author":"M Obasi","year":"2021","unstructured":"Obasi, M., Abovich, A., Vo, J. B., Gao, Y., Papatheodorou, S. I., Nohria, A., Asnani, A., & Partridge, A. H. (2021). Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and\/or trastuzumab: A systematic review and meta-analysis. Cancer Causes & Control, 32, 1395\u20131405.","journal-title":"Cancer Causes & Control"},{"key":"10107_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147439","author":"KJ Lee","year":"2021","unstructured":"Lee, K. J., Wright, G., Bryant, H., Wiggins, L. A., Dal Zotto, V. L., Schuler, M., Malozzi, C., Cohen, M. V., & Gassman, N. R. (2021). Cytoprotective effect of vitamin D on doxorubicin-induced cardiac toxicity in triple negative breast cancer. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms22147439","journal-title":"International Journal of Molecular Sciences"},{"key":"10107_CR62","doi-asserted-by":"crossref","unstructured":"Arsha, S., Tripathi, A., Kangarlu, J., Rehman, B., Frishman, W. H., & Aronow, W. S. (2025). Chemotherapy-Induced Cardiomyopathy: A Focus on the Utility of Statins. Cardiol Rev.","DOI":"10.1097\/CRD.0000000000000942"},{"key":"10107_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/1534735405276191","volume":"4","author":"KA Conklin","year":"2005","unstructured":"Conklin, K. A. (2005). Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies, 4, 110\u2013130.","journal-title":"Integrative Cancer Therapies"},{"key":"10107_CR64","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/10781552231171114","volume":"30","author":"I Moustafa","year":"2024","unstructured":"Moustafa, I., Connolly, C., Anis, M., Mustafa, H., Oosthuizen, F., & Viljoen, M. (2024). A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients. Journal of Oncology Pharmacy Practice\u202f: Official Publication of the International Society of Oncology Pharmacy Practitioners, 30, 354\u2013366.","journal-title":"Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners"},{"key":"10107_CR65","first-page":"631","volume":"32","author":"S Ramkumar","year":"2016","unstructured":"Ramkumar, S., Raghunath, A., & Raghunath, S. (2016). Statin therapy: Review of safety and potential side effects. Acta Cardiologica Sinica, 32, 631\u2013639.","journal-title":"Acta Cardiologica Sinica"},{"key":"10107_CR66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12325-023-02683-y","volume":"41","author":"TA Berezina","year":"2024","unstructured":"Berezina, T. A., Fushtey, I. M., Berezin, A. A., Pavlov, S. V., & Berezin, A. E. (2024). Predictors of kidney function outcomes and their relation to SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus who had chronic heart failure. Advanced Therapy, 41, 292\u2013314.","journal-title":"Advanced Therapy"},{"key":"10107_CR67","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1093\/eurjpc\/zwab189","volume":"29","author":"V Tsampasian","year":"2022","unstructured":"Tsampasian, V., Elghazaly, H., Chattopadhyay, R., Ali, O., Corballis, N., Chousou, P. A., Clark, A., Garg, P., & Vassiliou, V. S. (2022). Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 29, e227\u2013e229.","journal-title":"European Journal of Preventive Cardiology"},{"key":"10107_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf026","author":"U Bhalraam","year":"2025","unstructured":"Bhalraam, U., Veerni, R. B., Paddock, S., Meng, J., Piepoli, M., L\u00f3pez-Fern\u00e1ndez, T., Tsampasian, V., & Vassiliou, V. S. (2025). Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: A systematic review and meta-analysis. European Journal of Preventive Cardiology. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf026","journal-title":"European Journal of Preventive Cardiology"},{"key":"10107_CR69","first-page":"876","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour, M. S., Blaes, A. H., Ramu, B., & Zordoky, B. N. (2024). SGLT2 inhibitors in mitigating cancer therapy-related cardiac dysfunction: Expanding the evidence. JACC: CardioOncology, 6, 876\u2013878.","journal-title":"JACC: CardioOncology"},{"key":"10107_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy11020058","author":"M Aldhaeefi","year":"2023","unstructured":"Aldhaeefi, M., Beers, B., Shah, J., Rizi, S. S., Rungkitwattanakul, D., Nimoh, O., Frimpong, V., Gonzalez, J., Belrhiti, S., Urooj, F., & Williams, D. (2023). Sodium-glucose cotransporter-2 (SGLT-2) inhibitors use among heart failure patients and the role of pharmacists in early initiation of therapy. Pharmacy. https:\/\/doi.org\/10.3390\/pharmacy11020058","journal-title":"Pharmacy"},{"key":"10107_CR71","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","volume":"96","author":"WT Chang","year":"2022","unstructured":"Chang, W. T., Shih, J. Y., Lin, Y. W., Chen, Z. C., Kan, W. C., Lin, T. H., & Hong, C. S. (2022). Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Archives of Toxicology, 96, 2021\u20132032.","journal-title":"Archives of Toxicology"},{"key":"10107_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1289663","volume":"11","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Paccone, A., Maurea, C., Scherillo, M., Merola, A., Giordano, V., Palma, G., Luciano, A., Bruzzese, F., Zito Marino, F., Montella, M., Franco, R., Berretta, M., Gabrielli, D., Gallucci, G., & Maurea, N. (2024). Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-\u03baB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. Frontiers in Cardiovascular Medicine, 11, Article 1289663.","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10107_CR73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14796678.2024.2363673","volume":"20","author":"S Mohsin","year":"2024","unstructured":"Mohsin, S., Hasan, M., Sheikh, Z. M., Mustafa, F., Tegeltija, V., Kumar, S., & Kumar, J. (2024). Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: A meta-analysis in cancer patients. Future Cardiology, 20, 395\u2013407.","journal-title":"Future Cardiology"},{"key":"10107_CR74","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0378-1119(93)90495-O","volume":"136","author":"BF O'Dowd","year":"1993","unstructured":"O\u2019Dowd, B. F., Heiber, M., Chan, A., Heng, H. H., Tsui, L. C., Kennedy, J. L., Shi, X., Petronis, A., George, S. R., & Nguyen, T. (1993). A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene, 136, 355\u2013360.","journal-title":"Gene"},{"key":"10107_CR75","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","volume":"251","author":"K Tatemoto","year":"1998","unstructured":"Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M. X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., Kurokawa, T., Onda, H., & Fujino, M. (1998). Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications, 251, 471\u2013476.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10107_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054745","author":"B Fibbi","year":"2023","unstructured":"Fibbi, B., Marroncini, G., Naldi, L., & Peri, A. (2023). The yin and yang effect of the apelinergic system in oxidative stress. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms24054745","journal-title":"International Journal of Molecular Sciences"},{"key":"10107_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/j.2040-4603.2018.tb00012.x","volume":"8","author":"K Shin","year":"2017","unstructured":"Shin, K., Kenward, C., & Rainey, J. K. (2017). Apelinergic system structure and function. Comprehensive Physiology, 8, 407\u2013450.","journal-title":"Comprehensive Physiology"},{"key":"10107_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00221","volume":"8","author":"X Lv","year":"2017","unstructured":"Lv, X., Kong, J., Chen, W. D., & Wang, Y. D. (2017). The role of the apelin\/APJ system in the regulation of liver disease. Frontiers in Pharmacology, 8, Article 221.","journal-title":"Frontiers in Pharmacology"},{"key":"10107_CR79","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/cvr\/cvad171","volume":"119","author":"FA Chapman","year":"2023","unstructured":"Chapman, F. A., Maguire, J. J., Newby, D. E., Davenport, A. P., & Dhaun, N. (2023). Targeting the apelin system for the treatment of cardiovascular diseases. Cardiovascular Research, 119, 2683\u20132696.","journal-title":"Cardiovascular Research"},{"key":"10107_CR80","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.fob.2013.08.001","volume":"3","author":"K Shin","year":"2013","unstructured":"Shin, K., Pandey, A., Liu, X. Q., Anini, Y., & Rainey, J. K. (2013). Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity. FEBS Open Bio, 3, 328\u2013333.","journal-title":"FEBS Open Bio"},{"key":"10107_CR81","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-61779-204-5_3","volume":"768","author":"NG Seidah","year":"2011","unstructured":"Seidah, N. G. (2011). The proprotein convertases, 20 years later. Methods in Molecular Biology, 768, 23\u201357.","journal-title":"Methods in Molecular Biology"},{"key":"10107_CR82","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.bbagen.2017.05.017","volume":"1861","author":"K Shin","year":"2017","unstructured":"Shin, K., Chapman, N. A., Sarker, M., Kenward, C., Huang, S. K., Weatherbee-Martin, N., Pandey, A., Dupr\u00e9, D. J., & Rainey, J. K. (2017). Bioactivity of the putative apelin proprotein expands the repertoire of apelin receptor ligands. Biochimica et Biophysica Acta - General Subjects, 1861, 1901\u20131912.","journal-title":"Biochimica et Biophysica Acta - General Subjects"},{"key":"10107_CR83","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejmech.2019.01.040","volume":"166","author":"C Fischer","year":"2019","unstructured":"Fischer, C., Lamer, T., Wang, W., McKinnie, S. M. K., Iturrioz, X., Llorens-Cortes, C., Oudit, G. Y., & Vederas, J. C. (2019). Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents. European Journal of Medicinal Chemistry, 166, 119\u2013124.","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10107_CR84","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/cbic.201600244","volume":"17","author":"SM McKinnie","year":"2016","unstructured":"McKinnie, S. M., Fischer, C., Tran, K. M., Wang, W., Mosquera, F., Oudit, G. Y., & Vederas, J. C. (2016). The metalloprotease neprilysin degrades and inactivates apelin peptides. ChemBioChem, 17, 1495\u20131498.","journal-title":"ChemBioChem"},{"key":"10107_CR85","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"C Vickers","year":"2002","unstructured":"Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A., & Tummino, P. (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. Journal of Biological Chemistry, 277, 14838\u201314843.","journal-title":"Journal of Biological Chemistry"},{"key":"10107_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ab.2013.07.006","volume":"442","author":"EY Zhen","year":"2013","unstructured":"Zhen, E. Y., Higgs, R. E., & Gutierrez, J. A. (2013). Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Analytical Biochemistry, 442, 1\u20139.","journal-title":"Analytical Biochemistry"},{"key":"10107_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11835-z","volume":"12","author":"P Janssens","year":"2022","unstructured":"Janssens, P., de Loor, H., Decuypere, J. P., Vennekens, R., Llorens-Cortes, C., Mekahli, D., & Bammens, B. (2022). On methods for the measurement of the apelin receptor ligand apelin. Scientific Reports, 12, Article 7763.","journal-title":"Scientific Reports"},{"key":"10107_CR88","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.115.06892","volume":"68","author":"W Wang","year":"2016","unstructured":"Wang, W., McKinnie, S. M., Farhan, M., Paul, M., McDonald, T., McLean, B., Llorens-Cortes, C., Hazra, S., Murray, A. G., Vederas, J. C., & Oudit, G. Y. (2016). Angiotensin-converting enzyme 2 metabolizes and partially inactivates Pyr-apelin-13 and apelin-17: Physiological effects in the cardiovascular system. Hypertension, 68, 365\u2013377.","journal-title":"Hypertension"},{"key":"10107_CR89","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.bbadis.2016.11.007","volume":"1863","author":"JC Zhong","year":"2017","unstructured":"Zhong, J. C., Zhang, Z. Z., Wang, W., McKinnie, S. M. K., Vederas, J. C., & Oudit, G. Y. (2017). Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases. Biochimica et Biophysica Acta. Molecular Basis of Disease, 1863, 1942\u20131950.","journal-title":"Biochimica et Biophysica Acta. Molecular Basis of Disease"},{"key":"10107_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112172","author":"MN Ivanov","year":"2022","unstructured":"Ivanov, M. N., Stoyanov, D. S., Pavlov, S. P., & Tonchev, A. B. (2022). Distribution, function, and expression of the apelinergic system in the healthy and diseased mammalian brain. Genes. https:\/\/doi.org\/10.3390\/genes13112172","journal-title":"Genes"},{"key":"10107_CR91","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1139\/bcb-2014-0072","volume":"92","author":"NA Chapman","year":"2014","unstructured":"Chapman, N. A., Dupr\u00e9, D. J., & Rainey, J. K. (2014). The apelin receptor: Physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochemistry and Cell Biology, 92, 431\u2013440.","journal-title":"Biochemistry and Cell Biology"},{"key":"10107_CR92","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1021\/acs.jmedchem.0c01941","volume":"64","author":"K Tr\u00e2n","year":"2021","unstructured":"Tr\u00e2n, K., Van Den Hauwe, R., Sainsily, X., Couvineau, P., C\u00f4t\u00e9, J., Simard, L., Echevarria, M., Murza, A., Serre, A., Th\u00e9roux, L., Saibi, S., Haroune, L., Longpr\u00e9, J. M., Lesur, O., Auger-Messier, M., Spino, C., Bouvier, M., Sarret, P., Ballet, S., & Marsault, \u00c9. (2021). Constraining the side chain of C-terminal amino acids in apelin-13 greatly increases affinity, modulates signaling, and improves the pharmacokinetic profile. Journal of Medicinal Chemistry, 64, 5345\u20135364.","journal-title":"Journal of Medicinal Chemistry"},{"key":"10107_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55381-w","volume":"15","author":"TL Williams","year":"2024","unstructured":"Williams, T. L., Verdon, G., Kuc, R. E., Currinn, H., Bender, B., Solcan, N., Schlenker, O., Macrae, R. G. C., Brown, J., Sch\u00fctz, M., Zhukov, A., Sinha, S., de Graaf, C., Gr\u00e4f, S., Maguire, J. J., Brown, A. J. H., & Davenport, A. P. (2024). Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor. Nature Communications, 15, Article 10714.","journal-title":"Nature Communications"},{"key":"10107_CR94","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0167-0115(01)00236-1","volume":"99","author":"K Tatemoto","year":"2001","unstructured":"Tatemoto, K., Takayama, K., Zou, M. X., Kumaki, I., Zhang, W., Kumano, K., & Fujimiya, M. (2001). The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regulatory Peptides, 99, 87\u201392.","journal-title":"Regulatory Peptides"},{"key":"10107_CR95","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1210\/en.2004-0359","volume":"146","author":"DK Lee","year":"2005","unstructured":"Lee, D. K., Saldivia, V. R., Nguyen, T., Cheng, R., George, S. R., & O\u2019Dowd, B. F. (2005). Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology, 146, 231\u2013236.","journal-title":"Endocrinology"},{"key":"10107_CR96","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1745-7270.2008.00403.x","volume":"40","author":"B Bai","year":"2008","unstructured":"Bai, B., Tang, J., Liu, H., Chen, J., Li, Y., & Song, W. (2008). Apelin-13 induces ERK1\/2 but not p38 MAPK activation through coupling of the human apelin receptor to the Gi2 pathway. Acta Biochimica et Biophysica Sinica, 40, 311\u2013318.","journal-title":"Acta Biochimica et Biophysica Sinica"},{"key":"10107_CR97","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12079-021-00614-6","volume":"16","author":"S Dagamajalu","year":"2022","unstructured":"Dagamajalu, S., Rex, D. A. B., Philem, P. D., Rainey, J. K., & Keshava Prasad, T. S. (2022). A network map of apelin-mediated signaling. Journal of Cell Communication and Signaling, 16, 137\u2013143.","journal-title":"Journal of Cell Communication and Signaling"},{"key":"10107_CR98","doi-asserted-by":"publisher","first-page":"18317","DOI":"10.1074\/jbc.M600606200","volume":"281","author":"B Masri","year":"2006","unstructured":"Masri, B., Morin, N., Pedebernade, L., Knibiehler, B., & Audigier, Y. (2006). The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. Journal of Biological Chemistry, 281, 18317\u201318326.","journal-title":"Journal of Biological Chemistry"},{"key":"10107_CR99","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/en.2010-0576","volume":"152","author":"P Yue","year":"2011","unstructured":"Yue, P., Jin, H., Xu, S., Aillaud, M., Deng, A. C., Azuma, J., Kundu, R. K., Reaven, G. M., Quertermous, T., & Tsao, P. S. (2011). Apelin decreases lipolysis via G(q), G(i), and AMPK-dependent mechanisms. Endocrinology, 152, 59\u201368.","journal-title":"Endocrinology"},{"key":"10107_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbrc.2010.03.151","volume":"395","author":"DK Lee","year":"2010","unstructured":"Lee, D. K., Ferguson, S. S., George, S. R., & O\u2019Dowd, B. F. (2010). The fate of the internalized apelin receptor is determined by different isoforms of apelin mediating differential interaction with beta-arrestin. Biochemical and Biophysical Research Communications, 395, 185\u2013189.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10107_CR101","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature11263","volume":"488","author":"MC Scimia","year":"2012","unstructured":"Scimia, M. C., Hurtado, C., Ray, S., Metzler, S., Wei, K., Wang, J., Woods, C. E., Purcell, N. H., Catalucci, D., Akasaka, T., Bueno, O. F., Vlasuk, G. P., Kaliman, P., Bodmer, R., Smith, L. H., Ashley, E., Mercola, M., Brown, J. H., & Ruiz-Lozano, P. (2012). APJ acts as a dual receptor in cardiac hypertrophy. Nature, 488, 394\u2013398.","journal-title":"Nature"},{"key":"10107_CR102","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1139\/O09-129","volume":"88","author":"DN Langelaan","year":"2010","unstructured":"Langelaan, D. N., & Rainey, J. K. (2010). Membrane catalysis of peptide-receptor binding. Biochemistry and Cell Biology, 88, 203\u2013210.","journal-title":"Biochemistry and Cell Biology"},{"key":"10107_CR103","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1073\/pnas.83.16.5774","volume":"83","author":"DF Sargent","year":"1986","unstructured":"Sargent, D. F., & Schwyzer, R. (1986). Membrane lipid phase as catalyst for peptide-receptor interactions. Proceedings of the National Academy of Sciences of the United States of America, 83, 5774\u20135778.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10107_CR104","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.regpep.2003.11.002","volume":"118","author":"MJ Kleinz","year":"2004","unstructured":"Kleinz, M. J., & Davenport, A. P. (2004). Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regulatory Peptides, 118, 119\u2013125.","journal-title":"Regulatory Peptides"},{"key":"10107_CR105","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2017.00092","volume":"11","author":"P Yang","year":"2017","unstructured":"Yang, P., Kuc, R. E., Brame, A. L., Dyson, A., Singer, M., Glen, R. C., Cheriyan, J., Wilkinson, I. B., Davenport, A. P., & Maguire, J. J. (2017). [Pyr(1)]Apelin-13((1\u201312)) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr(1)]Apelin-13. Frontiers in Neuroscience, 11, 92.","journal-title":"Frontiers in Neuroscience"},{"key":"10107_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0167-4889(99)00114-7","volume":"1452","author":"Y Habata","year":"1999","unstructured":"Habata, Y., Fujii, R., Hosoya, M., Fukusumi, S., Kawamata, Y., Hinuma, S., Kitada, C., Nishizawa, N., Murosaki, S., Kurokawa, T., Onda, H., Tatemoto, K., & Fujino, M. (1999). Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochimica et Biophysica Acta, 1452, 25\u201335.","journal-title":"Biochimica et Biophysica Acta"},{"key":"10107_CR107","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1210\/en.2004-1427","volume":"146","author":"J Boucher","year":"2005","unstructured":"Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guign\u00e9, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carp\u00e9n\u00e9, C., Audigier, Y., Saulnier-Blache, J. S., & Valet, P. (2005). Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology, 146, 1764\u20131771.","journal-title":"Endocrinology"},{"key":"10107_CR108","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1874467213666200602133032","volume":"14","author":"T Kinjo","year":"2021","unstructured":"Kinjo, T., Higashi, H., Uno, K., & Kuramoto, N. (2021). Apelin\/Apelin receptor system: Molecular characteristics, physiological roles, and prospects as a target for disease prevention and pharmacotherapy. Current Molecular Pharmacology, 14, 210\u2013219.","journal-title":"Current Molecular Pharmacology"},{"key":"10107_CR109","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s11033-022-08075-9","volume":"50","author":"A Li","year":"2023","unstructured":"Li, A., Zhao, Q., Chen, L., & Li, Z. (2023). Apelin\/APJ system: An emerging therapeutic target for neurological diseases. Molecular Biology Reports, 50, 1639\u20131653.","journal-title":"Molecular Biology Reports"},{"key":"10107_CR110","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.regpep.2004.10.019","volume":"126","author":"MJ Kleinz","year":"2005","unstructured":"Kleinz, M. J., Skepper, J. N., & Davenport, A. P. (2005). Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regulatory Peptides, 126, 233\u2013240.","journal-title":"Regulatory Peptides"},{"key":"10107_CR111","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1002\/jcp.26144","volume":"233","author":"Z Huang","year":"2018","unstructured":"Huang, Z., Wu, L., & Chen, L. (2018). Apelin\/APJ system: A novel potential therapy target for kidney disease. Journal of Cellular Physiology, 233, 3892\u20133900.","journal-title":"Journal of Cellular Physiology"},{"key":"10107_CR112","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-014-0992-5","volume":"50","author":"S Yoshiya","year":"2015","unstructured":"Yoshiya, S., Shirabe, K., Imai, D., Toshima, T., Yamashita, Y., Ikegami, T., Okano, S., Yoshizumi, T., Kawanaka, H., & Maehara, Y. (2015). Blockade of the apelin-APJ system promotes mouse liver regeneration by activating Kupffer cells after partial hepatectomy. Journal of Gastroenterology, 50, 573\u2013582.","journal-title":"Journal of Gastroenterology"},{"key":"10107_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810600","author":"C Chaves-Almagro","year":"2022","unstructured":"Chaves-Almagro, C., Auriau, J., Dortignac, A., Clerc, P., Lulka, H., Deleruyelle, S., Projetti, F., Nakhl\u00e9, J., Frances, A., Berta, J., Gigoux, V., Fourmy, D., Dufresne, M., Gomez-Brouchet, A., Guillermet-Guibert, J., Cordelier, P., Knibiehler, B., Jockers, R., Valet, P., \u2026 Masri, B. (2022). Upregulated apelin signaling in pancreatic cancer activates oncogenic signaling pathways to promote tumor development. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms231810600","journal-title":"International Journal of Molecular Sciences"},{"key":"10107_CR114","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/JOE-13-0227","volume":"219","author":"AM O'Carroll","year":"2013","unstructured":"O\u2019Carroll, A. M., Lolait, S. J., Harris, L. E., & Pope, G. R. (2013). The apelin receptor APJ: Journey from an orphan to a multifaceted regulator of homeostasis. Journal of Endocrinology, 219, R13-35.","journal-title":"Journal of Endocrinology"},{"key":"10107_CR115","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.bcp.2007.12.015","volume":"75","author":"AG Japp","year":"2008","unstructured":"Japp, A. G., & Newby, D. E. (2008). The apelin-APJ system in heart failure: Pathophysiologic relevance and therapeutic potential. Biochemical Pharmacology, 75, 1882\u20131892.","journal-title":"Biochemical Pharmacology"},{"key":"10107_CR116","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cardiores.2007.02.002","volume":"74","author":"JC Zhong","year":"2007","unstructured":"Zhong, J. C., Yu, X. Y., Huang, Y., Yung, L. M., Lau, C. W., & Lin, S. G. (2007). Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovascular Research, 74, 388\u2013395.","journal-title":"Cardiovascular Research"},{"key":"10107_CR117","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000033522.37861.69","volume":"91","author":"I Szokodi","year":"2002","unstructured":"Szokodi, I., Tavi, P., F\u00f6ldes, G., Voutilainen-Myllyl\u00e4, S., Ilves, M., Tokola, H., Pikkarainen, S., Piuhola, J., Rys\u00e4, J., T\u00f3th, M., & Ruskoaho, H. (2002). Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circulation Research, 91, 434\u2013440.","journal-title":"Circulation Research"},{"key":"10107_CR118","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1089\/dna.2016.3391","volume":"35","author":"Z Chen","year":"2016","unstructured":"Chen, Z., Wu, D., Li, L., & Chen, L. (2016). Apelin\/APJ system: A novel therapeutic target for myocardial ischemia\/reperfusion injury. DNA and Cell Biology, 35, 766\u2013775.","journal-title":"DNA and Cell Biology"},{"key":"10107_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27889-6","volume":"13","author":"T Huang","year":"2023","unstructured":"Huang, T., Chen, D., Ye, W., Chen, W., Zhang, M., Hao, J., Xu, L., Bai, X., & Mao, S. (2023). Effect and mechanism of apelin on lipopolysaccharide induced acute pulmonary vascular endothelial barrier dysfunction. Scientific Reports, 13, Article 1560.","journal-title":"Scientific Reports"},{"key":"10107_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00120","volume":"8","author":"A Flahault","year":"2017","unstructured":"Flahault, A., Couvineau, P., Alvear-Perez, R., Iturrioz, X., & Llorens-Cortes, C. (2017). Role of the vasopressin\/apelin balance and potential use of metabolically stable apelin analogs in water metabolism disorders. Frontiers in Endocrinology (Lausanne), 8, Article 120.","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10107_CR121","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.peptides.2011.06.025","volume":"32","author":"H Chen","year":"2011","unstructured":"Chen, H., Zheng, C., Zhang, X., Li, J., Li, J., Zheng, L., & Huang, K. (2011). Apelin alleviates diabetes-associated endoplasmic reticulum stress in the pancreas of Akita mice. Peptides, 32, 1634\u20131639.","journal-title":"Peptides"},{"key":"10107_CR122","doi-asserted-by":"publisher","first-page":"G139","DOI":"10.1152\/ajpgi.00370.2012","volume":"305","author":"S Han","year":"2013","unstructured":"Han, S., Englander, E. W., Gomez, G. A., Aronson, J. F., Rastellini, C., Garofalo, R. P., Kolli, D., Quertermous, T., Kundu, R., & Greeley, G. H., Jr. (2013). Pancreatitis activates pancreatic apelin-APJ axis in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology, 305, G139-150.","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"key":"10107_CR123","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1210\/en.2014-1631","volume":"156","author":"S Han","year":"2015","unstructured":"Han, S., Englander, E. W., Gomez, G. A., Rastellini, C., Quertermous, T., Kundu, R. K., & Greeley, G. H., Jr. (2015). Pancreatic islet APJ deletion reduces islet density and glucose tolerance in mice. Endocrinology, 156, 2451\u20132460.","journal-title":"Endocrinology"},{"key":"10107_CR124","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.neuroscience.2024.12.025","volume":"566","author":"Z Huang","year":"2025","unstructured":"Huang, Z., Liu, Q., Guo, Q., Gao, J., Zhang, L., & Li, L. (2025). Effects and mechanisms of apelin in treating central nervous system diseases. Neuroscience, 566, 177\u2013189.","journal-title":"Neuroscience"},{"key":"10107_CR125","doi-asserted-by":"publisher","first-page":"331","DOI":"10.15283\/ijsc18133","volume":"12","author":"C Kim","year":"2019","unstructured":"Kim, C., Kim, H. J., Lee, H., Lee, H., Lee, S. J., Lee, S. T., Yang, S. R., & Chung, C. K. (2019). Mesenchymal stem cell transplantation promotes functional recovery through MMP2\/STAT3 related astrogliosis after spinal cord injury. International Journal of Stem Cells, 12, 331\u2013339.","journal-title":"International Journal of Stem Cells"},{"key":"10107_CR126","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.yjmcc.2006.07.004","volume":"41","author":"Y Iwanaga","year":"2006","unstructured":"Iwanaga, Y., Kihara, Y., Takenaka, H., & Kita, T. (2006). Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. Journal of Molecular and Cellular Cardiology, 41, 798\u2013806.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10107_CR127","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.peptides.2007.07.016","volume":"28","author":"YX Jia","year":"2007","unstructured":"Jia, Y. X., Lu, Z. F., Zhang, J., Pan, C. S., Yang, J. H., Zhao, J., Yu, F., Duan, X. H., Tang, C. S., & Qi, Y. F. (2007). Apelin activates L-arginine\/nitric oxide synthase\/nitric oxide pathway in rat aortas. Peptides, 28, 2023\u20132029.","journal-title":"Peptides"},{"key":"10107_CR128","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejheart.2005.10.007","volume":"8","author":"KS Chong","year":"2006","unstructured":"Chong, K. S., Gardner, R. S., Morton, J. J., Ashley, E. A., & McDonagh, T. A. (2006). Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. European Journal of Heart Failure, 8, 355\u2013360.","journal-title":"European Journal of Heart Failure"},{"key":"10107_CR129","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0006-291X(03)01424-4","volume":"308","author":"G F\u00f6ldes","year":"2003","unstructured":"F\u00f6ldes, G., Horkay, F., Szokodi, I., Vuolteenaho, O., Ilves, M., Lindstedt, K. A., M\u00e4yr\u00e4np\u00e4\u00e4, M., S\u00e1rm\u00e1n, B., Seres, L., Skoumal, R., Lak\u00f3-Fut\u00f3, Z., deCh\u00e2tel, R., Ruskoaho, H., & T\u00f3th, M. (2003). Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochemical and Biophysical Research Communications, 308, 480\u2013485.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10107_CR130","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.peptides.2009.02.010","volume":"30","author":"XJ Zeng","year":"2009","unstructured":"Zeng, X. J., Zhang, L. K., Wang, H. X., Lu, L. Q., Ma, L. Q., & Tang, C. S. (2009). Apelin protects heart against ischemia\/reperfusion injury in rat. Peptides, 30, 1144\u20131152.","journal-title":"Peptides"},{"key":"10107_CR131","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1161\/01.CIR.0000091235.94914.75","volume":"108","author":"MM Chen","year":"2003","unstructured":"Chen, M. M., Ashley, E. A., Deng, D. X., Tsalenko, A., Deng, A., Tabibiazar, R., Ben-Dor, A., Fenster, B., Yang, E., King, J. Y., Fowler, M., Robbins, R., Johnson, F. L., Bruhn, L., McDonagh, T., Dargie, H., Yakhini, Z., Tsao, P. S., & Quertermous, T. (2003). Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation, 108, 1432\u20131439.","journal-title":"Circulation"},{"key":"10107_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194420","author":"D Diakowska","year":"2021","unstructured":"Diakowska, D., Wyderka, R., Krzystek-Korpacka, M., Osuch, \u0141, Le\u015bk\u00f3w, A., So\u0142towska, A., Stanek, M., Rosi\u0144czuk, J., & Jaroch, J. (2021). Plasma levels of apelinergic system components in patients with chronic and acute coronary syndromes-a pilot study. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm10194420","journal-title":"Journal of Clinical Medicine"},{"key":"10107_CR133","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIRCRESAHA.107.158659","volume":"101","author":"K Kuba","year":"2007","unstructured":"Kuba, K., Zhang, L., Imai, Y., Arab, S., Chen, M., Maekawa, Y., Leschnik, M., Leibbrandt, A., Markovic, M., Schwaighofer, J., Beetz, N., Musialek, R., Neely, G. G., Komnenovic, V., Kolm, U., Metzler, B., Ricci, R., Hara, H., Meixner, A., \u2026 Penninger, J. M. (2007). Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circulation Research, 101, e32-42.","journal-title":"Circulation Research"},{"key":"10107_CR134","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4823156","volume":"2019","author":"Q Ouyang","year":"2019","unstructured":"Ouyang, Q., You, T., Guo, J., Xu, R., Guo, Q., Lin, J., & Zhao, H. (2019). Effects of apelin on left ventricular-arterial coupling and mechanical efficiency in rats with ischemic heart failure. Disease Markers, 2019, Article 4823156.","journal-title":"Disease Markers"},{"key":"10107_CR135","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/eurheartj\/ehr389","volume":"33","author":"D Pchejetski","year":"2012","unstructured":"Pchejetski, D., Foussal, C., Alfarano, C., Lairez, O., Calise, D., Guilbeau-Frugier, C., Schaak, S., Seguelas, M. H., Wanecq, E., Valet, P., Parini, A., & Kunduzova, O. (2012). Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. European Heart Journal, 33, 2360\u20132369.","journal-title":"European Heart Journal"},{"key":"10107_CR136","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cca.2011.11.021","volume":"413","author":"AM Tycinska","year":"2012","unstructured":"Tycinska, A. M., Lisowska, A., Musial, W. J., & Sobkowicz, B. (2012). Apelin in acute myocardial infarction and heart failure induced by ischemia. Clinica Chimica Acta, 413, 406\u2013410.","journal-title":"Clinica Chimica Acta"},{"key":"10107_CR137","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/CIRCHEARTFAILURE.111.000077","volume":"6","author":"GD Barnes","year":"2013","unstructured":"Barnes, G. D., Alam, S., Carter, G., Pedersen, C. M., Lee, K. M., Hubbard, T. J., Veitch, S., Jeong, H., White, A., Cruden, N. L., Huson, L., Japp, A. G., & Newby, D. E. (2013). Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circulation. Heart Failure, 6, 482\u2013491.","journal-title":"Circulation. Heart Failure"},{"key":"10107_CR138","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/bph.13485","volume":"173","author":"F Boal","year":"2016","unstructured":"Boal, F., Timotin, A., Roumegoux, J., Alfarano, C., Calise, D., Anesia, R., Parini, A., Valet, P., Tronchere, H., & Kunduzova, O. (2016). Apelin-13 administration protects against ischaemia\/reperfusion-mediated apoptosis through the FoxO1 pathway in high-fat diet-induced obesity. British Journal of Pharmacology, 173, 1850\u20131863.","journal-title":"British Journal of Pharmacology"},{"key":"10107_CR139","doi-asserted-by":"publisher","first-page":"H1904","DOI":"10.1152\/ajpheart.00686.2009","volume":"297","author":"DN Charo","year":"2009","unstructured":"Charo, D. N., Ho, M., Fajardo, G., Kawana, M., Kundu, R. K., Sheikh, A. Y., Finsterbach, T. P., Leeper, N. J., Ernst, K. V., Chen, M. M., Ho, Y. D., Chun, H. J., Bernstein, D., Ashley, E. A., & Quertermous, T. (2009). Endogenous regulation of cardiovascular function by apelin-APJ. American Journal of Physiology. Heart and Circulatory Physiology, 297, H1904-1913.","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10107_CR140","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.febslet.2010.04.025","volume":"584","author":"C Foussal","year":"2010","unstructured":"Foussal, C., Lairez, O., Calise, D., Pathak, A., Guilbeau-Frugier, C., Valet, P., Parini, A., & Kunduzova, O. (2010). Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Letters, 584, 2363\u20132370.","journal-title":"FEBS Letters"},{"key":"10107_CR141","doi-asserted-by":"publisher","first-page":"H931","DOI":"10.1152\/ajpheart.00703.2013","volume":"308","author":"J Hamada","year":"2015","unstructured":"Hamada, J., Baasanjav, A., Ono, N., Murata, K., Kako, K., Ishida, J., & Fukamizu, A. (2015). Possible involvement of downregulation of the apelin-APJ system in doxorubicin-induced cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 308, H931-941.","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10107_CR142","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.regpep.2005.09.033","volume":"133","author":"YX Jia","year":"2006","unstructured":"Jia, Y. X., Pan, C. S., Zhang, J., Geng, B., Zhao, J., Gerns, H., Yang, J., Chang, J. K., Tang, C. S., & Qi, Y. F. (2006). Apelin protects myocardial injury induced by isoproterenol in rats. Regulatory Peptides, 133, 147\u2013154.","journal-title":"Regulatory Peptides"},{"key":"10107_CR143","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200040","author":"S Zhong","year":"2020","unstructured":"Zhong, S., Guo, H., Wang, H., Xing, D., Lu, T., Yang, J., & Wang, C. (2020). Apelin-13 alleviated cardiac fibrosis via inhibiting the PI3K\/Akt pathway to attenuate oxidative stress in rats with myocardial infarction-induced heart failure. Bioscience Reports. https:\/\/doi.org\/10.1042\/BSR20200040","journal-title":"Bioscience Reports"},{"key":"10107_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/srep16104","volume":"5","author":"F Boal","year":"2015","unstructured":"Boal, F., Roumegoux, J., Alfarano, C., Timotin, A., Calise, D., Anesia, R., Drougard, A., Knauf, C., Lagente, C., Roncalli, J., Desmoulin, F., Tronchere, H., Valet, P., Parini, A., & Kunduzova, O. (2015). Apelin regulates FoxO3 translocation to mediate cardioprotective responses to myocardial injury and obesity. Scientific Reports, 5, Article 16104.","journal-title":"Scientific Reports"},{"key":"10107_CR145","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.cjca.2024.11.034","volume":"41","author":"PE Girault-Sotias","year":"2025","unstructured":"Girault-Sotias, P. E., Deloux, R., De Mota, N., Rich\u00e9, S., Daubeuf, F., Iturrioz, X., Parlakian, A., Berdeaux, A., Agbulut, O., Bonnet, D., Boitard, S. E., & Llorens-Cortes, C. (2025). The metabolically resistant Apelin-17 analogue LIT01-196 reduces cardiac dysfunction and remodelling in heart failure after myocardial infarction. Canadian Journal of Cardiology, 41, 911\u2013924.","journal-title":"Canadian Journal of Cardiology"},{"key":"10107_CR146","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/HJH.0b013e32834347de","volume":"29","author":"K Siddiquee","year":"2011","unstructured":"Siddiquee, K., Hampton, J., Khan, S., Zadory, D., Gleaves, L., Vaughan, D. E., & Smith, L. H. (2011). Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. Journal of Hypertension, 29, 724\u2013731.","journal-title":"Journal of Hypertension"},{"key":"10107_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.715095","volume":"12","author":"A Flahault","year":"2021","unstructured":"Flahault, A., Keck, M., Girault-Sotias, P. E., Esteoulle, L., De Mota, N., Bonnet, D., & Llorens-Cortes, C. (2021). LIT01-196, a metabolically stable Apelin-17 analog, normalizes blood pressure in hypertensive DOCA-salt rats via a NO synthase-dependent mechanism. Frontiers in Pharmacology, 12, Article 715095.","journal-title":"Frontiers in Pharmacology"},{"key":"10107_CR148","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1111\/bph.13038","volume":"172","author":"O Pisarenko","year":"2015","unstructured":"Pisarenko, O., Shulzhenko, V., Studneva, I., Pelogeykina, Y., Timoshin, A., Anesia, R., Valet, P., Parini, A., & Kunduzova, O. (2015). Structural apelin analogues: Mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia reperfusion injury. British Journal of Pharmacology, 172, 2933\u20132945.","journal-title":"British Journal of Pharmacology"},{"key":"10107_CR149","first-page":"2360","volume":"122","author":"Z Zhang","year":"2009","unstructured":"Zhang, Z., Yu, B., & Tao, G. Z. (2009). Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chinese Medical Journal (English Edition), 122, 2360\u20132365.","journal-title":"Chinese Medical Journal (English Edition)"},{"key":"10107_CR150","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCULATIONAHA.109.911339","volume":"121","author":"AG Japp","year":"2010","unstructured":"Japp, A. G., Cruden, N. L., Barnes, G., van Gemeren, N., Mathews, J., Adamson, J., Johnston, N. R., Denvir, M. A., Megson, I. L., Flapan, A. D., & Newby, D. E. (2010). Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure. Circulation, 121, 1818\u20131827.","journal-title":"Circulation"},{"key":"10107_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097898","author":"SK Masenga","year":"2023","unstructured":"Masenga, S. K., Kabwe, L. S., Chakulya, M., & Kirabo, A. (2023). Mechanisms of oxidative stress in metabolic syndrome. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms24097898","journal-title":"International Journal of Molecular Sciences"},{"key":"10107_CR152","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1152\/physrev.00030.2020","volume":"101","author":"J Ren","year":"2021","unstructured":"Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021). Obesity cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Physiological Reviews, 101, 1745\u20131807.","journal-title":"Physiological Reviews"},{"key":"10107_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.886553","volume":"9","author":"K Schimmel","year":"2022","unstructured":"Schimmel, K., Ichimura, K., Reddy, S., Haddad, F., & Spiekerkoetter, E. (2022). Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target. Frontiers in Cardiovascular Medicine, 9, Article 886553.","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10107_CR154","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/CIRCRESAHA.124.323658","volume":"134","author":"I Hilgendorf","year":"2024","unstructured":"Hilgendorf, I., Frantz, S., & Frangogiannis, N. G. (2024). Repair of the infarcted heart: Cellular effectors, molecular mechanisms and therapeutic opportunities. Circulation Research, 134, 1718\u20131751.","journal-title":"Circulation Research"},{"key":"10107_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/cells15020173","author":"DM Lazovi\u0107","year":"2026","unstructured":"Lazovi\u0107, D. M., Karad\u017ei\u0107 Ko\u010dica, M., Ivani\u0161evi\u0107, D., Aleksi\u0107, V., Ko\u010dica, M. J., Gruji\u0107, D., Mihajlovi\u0107, J. M., Cvetkovi\u0107, D., & Juri\u010di\u0107, S. A. (2026). Molecular and cellular mechanisms of cardioplegic protection in surgical myocardial revascularization. Cells. https:\/\/doi.org\/10.3390\/cells15020173","journal-title":"Cells"},{"key":"10107_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/biom15101416","author":"B Akca","year":"2025","unstructured":"Akca, B., Disli, O. M., Erdil, N., Cigremis, Y., Ozen, H., Durhan, M., Tunc, S., Ozhan, O., Ulutas, Z., & Erdil, F. A. (2025). Curcumin alleviates doxorubicin-induced cardiotoxicity by modulating apelin expression. Biomolecules. https:\/\/doi.org\/10.3390\/biom15101416","journal-title":"Biomolecules"},{"key":"10107_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010094","author":"K Buczma","year":"2025","unstructured":"Buczma, K., Borzuta, H., Kami\u0144ska, K., Sztechman, D., Matusik, K., Pawlonka, J., Kowara, M., Buchalska, B., & Cudnoch-J\u0119drzejewska, A. (2025). Apelinergic system affects electrocardiographic abnormalities induced by doxorubicin. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13010094","journal-title":"Biomedicines"},{"key":"10107_CR158","doi-asserted-by":"publisher","first-page":"H1471","DOI":"10.1152\/ajpheart.00097.2011","volume":"301","author":"J Tao","year":"2011","unstructured":"Tao, J., Zhu, W., Li, Y., Xin, P., Li, J., Liu, M., Li, J., Redington, A. N., & Wei, M. (2011). Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. American Journal of Physiology. Heart and Circulatory Physiology, 301, H1471-1486.","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10107_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.850053","volume":"13","author":"W Liao","year":"2022","unstructured":"Liao, W., Rao, Z., Wu, L., Chen, Y., & Li, C. (2022). Cariporide attenuates doxorubicin-induced cardiotoxicity in rats by inhibiting oxidative stress, inflammation and apoptosis partly through regulation of Akt\/GSK-3\u03b2 and Sirt1 signaling pathway. Frontiers in Pharmacology, 13, Article 850053.","journal-title":"Frontiers in Pharmacology"},{"key":"10107_CR160","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1124\/jpet.107.125773","volume":"324","author":"KH Kim","year":"2008","unstructured":"Kim, K. H., Oudit, G. Y., & Backx, P. H. (2008). Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. Journal of Pharmacology and Experimental Therapeutics, 324, 160\u2013169.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10107_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00815","volume":"11","author":"L Li","year":"2020","unstructured":"Li, L., Li, J., Wang, Q., Zhao, X., Yang, D., Niu, L., Yang, Y., Zheng, X., Hu, L., & Li, Y. (2020). Shenmai injection protects against doxorubicin-induced cardiotoxicity via maintaining mitochondrial homeostasis. Frontiers in Pharmacology, 11, Article 815.","journal-title":"Frontiers in Pharmacology"},{"key":"10107_CR162","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2337\/db11-0100","volume":"61","author":"C Attan\u00e9","year":"2012","unstructured":"Attan\u00e9, C., Foussal, C., Le Gonidec, S., Benani, A., Daviaud, D., Wanecq, E., Guzm\u00e1n-Ruiz, R., Dray, C., Bezaire, V., Rancoule, C., Kuba, K., Ruiz-Gayo, M., Levade, T., Penninger, J., Burcelin, R., P\u00e9nicaud, L., Valet, P., & Castan-Laurell, I. (2012). Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes, 61, 310\u2013320.","journal-title":"Diabetes"},{"key":"10107_CR163","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2005.05.004","volume":"1","author":"J Lin","year":"2005","unstructured":"Lin, J., Handschin, C., & Spiegelman, B. M. (2005). Metabolic control through the PGC-1 family of transcription coactivators. Cell Metabolism, 1, 361\u2013370.","journal-title":"Cell Metabolism"},{"key":"10107_CR164","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbagen.2011.05.004","volume":"1810","author":"T Yamamoto","year":"2011","unstructured":"Yamamoto, T., Habata, Y., Matsumoto, Y., Yasuhara, Y., Hashimoto, T., Hamajyo, H., Anayama, H., Fujii, R., Fuse, H., Shintani, Y., & Mori, M. (2011). Apelin-transgenic mice exhibit a resistance against diet-induced obesity by increasing vascular mass and mitochondrial biogenesis in skeletal muscle. Biochimica et Biophysica Acta, 1810, 853\u2013862.","journal-title":"Biochimica et Biophysica Acta"},{"key":"10107_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093473","volume":"9","author":"\u00c1 Perj\u00e9s","year":"2014","unstructured":"Perj\u00e9s, \u00c1., Skoumal, R., Tenhunen, O., K\u00f3nyi, A., Simon, M., Horv\u00e1th, I. G., Kerkel\u00e4, R., Ruskoaho, H., & Szokodi, I. (2014). Apelin increases cardiac contractility via protein kinase C\u03b5- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One, 9, Article e93473.","journal-title":"PLoS One"},{"key":"10107_CR166","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacc.2008.06.013","volume":"52","author":"AG Japp","year":"2008","unstructured":"Japp, A. G., Cruden, N. L., Amer, D. A., Li, V. K., Goudie, E. B., Johnston, N. R., Sharma, S., Neilson, I., Webb, D. J., Megson, I. L., Flapan, A. D., & Newby, D. E. (2008). Vascular effects of apelin in vivo in man. Journal of the American College of Cardiology, 52, 908\u2013913.","journal-title":"Journal of the American College of Cardiology"},{"key":"10107_CR167","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/cvr\/cvp056","volume":"82","author":"N Gellings Lowe","year":"2009","unstructured":"Gellings Lowe, N., Swaney, J. S., Moreno, K. M., & Sabbadini, R. A. (2009). Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovascular Research, 82, 303\u2013312.","journal-title":"Cardiovascular Research"},{"key":"10107_CR168","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cellsig.2004.09.018","volume":"17","author":"B Masri","year":"2005","unstructured":"Masri, B., Knibiehler, B., & Audigier, Y. (2005). Apelin signalling: A promising pathway from cloning to pharmacology. Cellular Signalling, 17, 415\u2013426.","journal-title":"Cellular Signalling"},{"key":"10107_CR169","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1096\/fj.201600784R","volume":"31","author":"R Gerbier","year":"2017","unstructured":"Gerbier, R., Alvear-Perez, R., Margathe, J. F., Flahault, A., Couvineau, P., Gao, J., De Mota, N., Dabire, H., Li, B., Ceraudo, E., Hus-Citharel, A., Esteoulle, L., Bisoo, C., Hibert, M., Berdeaux, A., Iturrioz, X., Bonnet, D., & Llorens-Cortes, C. (2017). Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects. FASEB Journal, 31, 687\u2013700.","journal-title":"FASEB Journal"},{"key":"10107_CR170","first-page":"547","volume":"22","author":"J Hamada","year":"2008","unstructured":"Hamada, J., Kimura, J., Ishida, J., Kohda, T., Morishita, S., Ichihara, S., & Fukamizu, A. (2008). Evaluation of novel cyclic analogues of apelin. International Journal of Molecular Medicine, 22, 547\u2013552.","journal-title":"International Journal of Molecular Medicine"},{"key":"10107_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735515","volume":"12","author":"PE Girault-Sotias","year":"2021","unstructured":"Girault-Sotias, P. E., Gerbier, R., Flahault, A., de Mota, N., & Llorens-Cortes, C. (2021). Apelin and vasopressin: The Yin and Yang of water balance. Frontiers in Endocrinology (Lausanne), 12, Article 735515.","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10107_CR172","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1039\/D1MD00120E","volume":"12","author":"KX Fernandez","year":"2021","unstructured":"Fernandez, K. X., Fischer, C., Vu, J., Gheblawi, M., Wang, W., Gottschalk, S., Iturrioz, X., Llorens-Cort\u00e9s, C., Oudit, G. Y., & Vederas, J. C. (2021). Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators. RSC Medicinal Chemistry, 12, 1402\u20131413.","journal-title":"RSC Medicinal Chemistry"},{"key":"10107_CR173","doi-asserted-by":"publisher","first-page":"13006","DOI":"10.1073\/pnas.1900152116","volume":"116","author":"W Wang","year":"2019","unstructured":"Wang, W., Shen, M., Fischer, C., Basu, R., Hazra, S., Couvineau, P., Paul, M., Wang, F., Toth, S., Mix, D. S., Poglitsch, M., Gerard, N. P., Bouvier, M., Vederas, J. C., Penninger, J. M., Kassiri, Z., & Oudit, G. Y. (2019). Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proceedings of the National Academy of Sciences of the United States of America, 116, 13006\u201313015.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10107_CR174","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer, M., McMurray, J. J., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M., Andersen, K., Arango, J. L., Arnold, J. M., B\u011blohl\u00e1vek, J., B\u00f6hm, M., Boytsov, S., Burgess, L. J., Cabrera, W., \u2026 Wong, R. C. (2015). Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation, 131, 54\u201361.","journal-title":"Circulation"},{"key":"10107_CR175","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.114.05099","volume":"65","author":"AL Brame","year":"2015","unstructured":"Brame, A. L., Maguire, J. J., Yang, P., Dyson, A., Torella, R., Cheriyan, J., Singer, M., Glen, R. C., Wilkinson, I. B., & Davenport, A. P. (2015). Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension, 65, 834\u2013840.","journal-title":"Hypertension"},{"key":"10107_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040600","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q., Shen, Y., Niloy, S. I., O\u2019Rourke, S. T., & Sun, C. (2023). Chronic effects of apelin on cardiovascular regulation and angiotensin II-induced hypertension. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16040600","journal-title":"Pharmaceuticals (Basel)"},{"key":"10107_CR177","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/sj.emboj.7601982","volume":"27","author":"H Kidoya","year":"2008","unstructured":"Kidoya, H., Ueno, M., Yamada, Y., Mochizuki, N., Nakata, M., Yano, T., Fujii, R., & Takakura, N. (2008). Spatial and temporal role of the apelin\/APJ system in the caliber size regulation of blood vessels during angiogenesis. The EMBO Journal, 27, 522\u2013534.","journal-title":"The EMBO Journal"},{"key":"10107_CR178","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1161\/CIRCRESAHA.108.179333","volume":"103","author":"M Eyries","year":"2008","unstructured":"Eyries, M., Siegfried, G., Ciumas, M., Montagne, K., Agrapart, M., Lebrin, F., & Soubrier, F. (2008). Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circulation Research, 103, 432\u2013440.","journal-title":"Circulation Research"},{"key":"10107_CR179","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cardiores.2004.08.018","volume":"65","author":"EA Ashley","year":"2005","unstructured":"Ashley, E. A., Powers, J., Chen, M., Kundu, R., Finsterbach, T., Caffarelli, A., Deng, A., Eichhorn, J., Mahajan, R., Agrawal, R., Greve, J., Robbins, R., Patterson, A. J., Bernstein, D., & Quertermous, T. (2005). The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovascular Research, 65, 73\u201382.","journal-title":"Cardiovascular Research"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10107-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T02:03:04Z","timestamp":1779501784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":179,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10107"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10107-w","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"44"}}